Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia

Dispinseri, Stefania; Lampasona, Vito; Secchi, Massimiliano; Cara, Andrea; Bazzigaluppi, Elena; Negri, Donatella; Brigatti, Cristina; Pirillo, Maria Franca; Marzinotto, Ilaria; Borghi, Martina; Rovere‐Querini, Patrizia; Tresoldi, Cristina; Ciceri, Fabio; Scavini, Marina; Scarlatti, Gabriella; Piemonti, Lorenzo

doi:10.1210/clinem/dgab055

Cited by 38 publications

(45 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 2 A recent excellent systematic review on the immune response in Covid‐19 patients reported the earliest detectability of IgG to occur at a median of 12 days PSO or PCR‐confirmed diagnosis, to reach a peak at a median of 25 days and to start declining around 60 days. 23 Findings on IgG persistence are largely consistent across studies with positive IgG results being reported for all time points of serological testing, 12 , 15 , 17 , 20 , 21 , 25 , 26 , 27 , 28 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 up to 34–35 weeks PSO. 40 , 55 Whereas Hartley et al.…”

Section: Persistence Of Humoral Responsesupporting

confidence: 67%

“…The majority of studies reported durability of IgM responses for up to 30–31 weeks, the longest time point studied. 15 , 20 , 31 , 32 , 37 , 38 , 44 , 45 , 56 , 59 Five studies reported initially positive findings followed by negative ones 21 , 36 , 43 , 54 , 59 detected as early as 14–15 weeks 21 , 43 and as late as 26–31 weeks 36 post infection. Another study reported mixed findings for different cohorts and antigens tested.…”

Section: Persistence Of Humoral Responsementioning

confidence: 99%

“…Findings on NAbs were quite consistent across reviewed studies, with the majority studies observing positive NAbs at all time points tested. 15 , 17 , 20 , 25 , 26 , 27 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 43 , 44 , 47 , 48 , 49 , 51 , 52 , 53 , 54 , 55 , 56 , 58 Dan et al. using a pVNT found the most durable NAb response to last up to 34–35 weeks post PSO/PCR.…”

Section: Neutralizing Humoral Responsementioning

confidence: 99%

See 2 more Smart Citations

Persistence of humoral response upon SARS‐CoV‐2 infection

Knies

Braun

Kimpel

et al. 2021

Reviews in Medical Virology

View full text Add to dashboard Cite

Summary SARS‐CoV‐2 continues to leave its toll on global health and the economy. Management of the pandemic will rely heavily on the degree of adaptive immunity persistence following natural SARS‐CoV‐2 infection. Along with the progression of the pandemic, more literature on the persistence of the SARS‐CoV‐2‐specific antibody response is becoming available. Here, we summarize findings on the persistence of the humoral, including neutralizing antibody, response at three to eight months post SARS‐CoV‐2 infection in non‐pregnant adults. While the comparability of the literature is limited, findings on the detectability of immunoglobulin G class of antibodies (IgG) were most consistent and were reported in most studies to last for six to eight months. Studies investigating the response of immunoglobins M and A (IgM, IgA) were limited and reported mixed results, in particular, for IgM. The majority of studies observed neutralizing antibodies at all time points tested, which in some studies lasted up to eight months. The presence of neutralizing antibodies has been linked to protection from re‐infection, suggesting long‐term immunity to SARS‐CoV‐2. These neutralizing capacities may be challenged by emerging virus variants, but mucosal antibodies as well as memory B and T cells may optimize future immune responses. Thus, further longitudinal investigation of PCR‐confirmed seropositive individuals using sensitive assays is warranted to elucidate the nature and duration of a more long‐term humoral response.

show abstract

Section: Persistence Of Humoral Responsesupporting

confidence: 67%

Section: Persistence Of Humoral Responsementioning

confidence: 99%

Section: Neutralizing Humoral Responsementioning

confidence: 99%

See 1 more Smart Citation

Persistence of humoral response upon SARS‐CoV‐2 infection

Knies

Braun

Kimpel

et al. 2021

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…Dispinseri et al showed that anti SARS-CoV-2 neutralizing antibodies' (Nabs) kinetic and durability were not affected by diabetes/hyperglycemia status. More importantly, Nabs positivity at the time of hospital admission conferred a protective effect, independent of diabetes status (HR 0.28, p = 0.046 (with diabetes), HR 0.26, p = 0.030 (without diabetes) [102].…”

Section: Vaccinating Diabetes Communitiesmentioning

confidence: 96%

Diabetes and COVID-19: The past, the present, and the future

Pranata

Henrina²,

Raffaello

et al. 2021

Metabolism

View full text Add to dashboard Cite

Diabetes, one of the most prevalent chronic diseases in the world, is strongly associated with a poor prognosis in COVID-19. Scrupulous blood sugar management is crucial, since the worse outcomes are closely associated with higher blood sugar levels in COVID-19 infection. Although recent observational studies showed that insulin was associated with mortality, it should not deter insulin use in hospitalized patients requiring tight glucose control. Back and forth dilemma in the past with regards to continue/discontinue certain medications used in diabetes have been mostly resolved. The initial fears of consequences related to continuing certain medications have been largely dispelled. COVID-19 also necessitates the transformation in diabetes care through the integration of technologies. Recent advances in health-related technologies, notably telemedicine and remote continuous glucose monitoring, have become essential in the management of diabetes during the pandemic. Today, these technologies have changed the landscape of medicine and become more important than ever. Being a highrisk population, patients with type 1 or type 2 diabetes, should be prioritized for vaccination. In the future, as the pandemic fades, the prevalence of non-communicable diseases is expected to rise due to lifestyle changes and medical issues/dilemma encountered during the pandemic.

show abstract

“…Routine blood tests encompassed serum biochemistry [including renal and liver function, lactate dehydrogenase (LDH)], complete blood count with differential and C-reactive protein (CRP) as inflammation marker. Specific antibodies to different SARS-CoV-2 antigens, interferon alpha-4 and glutamic acid decarboxylase (GAD) were measured by a luciferase immunoprecipitation system (LIPS) assay, as previously described [20][21][22][23].…”

Section: Laboratory Variablesmentioning

confidence: 99%

Dysglycemia after COVID-19 pneumonia: a six-month cohort study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Aim The aim of this study was to understand whether the dysglycemia associated with SARS-CoV-2 infection persists or reverts when the viral infection resolves. Methods We analyzed fasting blood glucose (FBG) after hospital discharge in a cohort of 621 adult cases with suspected COVID-19 pneumonia. Results At admission, 18.8% of the patients in our cohort had pre-existing diabetes, 9.3% fasting glucose in the diabetes range without a prior diagnosis (DFG), 26% impaired fasting glucose (IFG), 44.9% normal fasting glucose (NFG), while 2% had no FBG available. FBG categories were similarly distributed in the 71 patients without confirmed COVID-19 pneumonia. During follow-up (median time 6 month) FBG was available for 321 out of the 453 (70.9%) surviving patients and showed a trend to a marginal increase [from 97 (87-116) to 100 (92-114) mg/dL; p = 0.071]. Transitions between FBG categories were analyzed in subjects without pre-existing diabetes (265 out of 321). We identified three groups: (i) patients who maintained or improved FBG during follow-up [Group A, n = 185; from 100 (86-109) to 94 (88-99) mg/dL; p < 0.001]; (ii) patients who moved from the NFG to IFG category [Group B, n = 66: from 89 (85-96) to 106 (102-113) mg/dl; p < 0.001]; (iii) patients who maintained or reached DFG during follow-up [Group C, n = 14: from 114 (94-138) to 134 (126-143) mg/dl; p = 0.035]. Male sex and ICU admission during the hospitalization were more prevalent in Group C compared to Group A or B. Conclusions Six months after the SARS-CoV-2 infection DFG was evident in only few patients who experienced severe COVID-19 pneumonia.

show abstract

Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia

Cited by 38 publications

References 46 publications

Persistence of humoral response upon SARS‐CoV‐2 infection

Persistence of humoral response upon SARS‐CoV‐2 infection

Diabetes and COVID-19: The past, the present, and the future

Dysglycemia after COVID-19 pneumonia: a six-month cohort study

Contact Info

Product

Resources

About